Elevance Health Dirección
Dirección controles de criterios 3/4
El CEO de Elevance Health's es Gail Boudreaux , nombrado en Nov 2017, tiene una permanencia de 6.42 años. compensación anual total es $21.89M, compuesta por 7.3% salario y 92.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.062% de las acciones de la empresa, por valor de $77.72M. La antigüedad media del equipo directivo y de la junta directiva es de 6 años y 10.7 años, respectivamente.
Información clave
Gail Boudreaux
Chief Executive Officer (CEO)
US$21.9m
Compensación total
| Porcentaje del salario del CEO | 7.3% |
| Permanencia del CEO | 6.5yrs |
| Participación del CEO | 0.06% |
| Permanencia media de la dirección | 6.1yrs |
| Promedio de permanencia en la Junta Directiva | 10.8yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Shareholders Will Probably Be Generous With Elevance Health, Inc.'s (NYSE:ELV) CEO Compensation
May 09
Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63
Apr 25Elevance Health: It's Not Too Late To Buy Their Dividend Growth
Apr 23Is Elevance Health (NYSE:ELV) Using Too Much Debt?
Apr 16Elevance Health: Not Doing Enough In 2024 To Justify Premium Price
Apr 11Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors
Apr 01Elevance: A Healthy Dose Of Dividend Growth
Mar 21Elevance Heath: Financial Growth And Technical Strength Indicate A Buy
Mar 07Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63
Feb 19Elevance Health: Time To Buy This Incredible Dividend Growth Stock
Jan 26Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement
Jan 19Is Elevance Health (NYSE:ELV) A Risky Investment?
Jan 02Elevance Health, Inc.'s (NYSE:ELV) Shares Not Telling The Full Story
Dec 18A Look At Elevance's Margin Dynamics
Nov 23Is It Time To Consider Buying Elevance Health, Inc. (NYSE:ELV)?
Nov 16Elevance Health: A High Conviction Defensive Blue Chip Buy
Oct 19These 4 Measures Indicate That Elevance Health (NYSE:ELV) Is Using Debt Safely
Oct 04Elevance: Pave The Way For The Next UnitedHealth
Sep 21Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Sep 18Here's The Price I Would Buy Elevance Health Stock
Sep 13If EPS Growth Is Important To You, Elevance Health (NYSE:ELV) Presents An Opportunity
Aug 18Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
Aug 04Narrowing Down High-Quality Dividend Growth: Elevance Health Is Elemental
Jul 24Elevance Health: Beaten Down Share Price Offers Solid Potential
Jul 10Here's Why Elevance Health (NYSE:ELV) Can Manage Its Debt Responsibly
Jul 05Elevance Health: A Critical Update (Rating Downgrade)
Jun 05Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
Jun 04Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
May 05We Think Elevance Health (NYSE:ELV) Can Stay On Top Of Its Debt
Apr 04Elevance Health's (NYSE:ELV) Dividend Will Be Increased To $1.48
Feb 17Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Feb 13Elevance Health: Attractive On Its Expansion Catalysts
Feb 09Elevance Health (NYSE:ELV) Has Announced That It Will Be Increasing Its Dividend To $1.48
Jan 28Elevance Health acquiring Blue Cross and Blue Shield of Louisiana
Jan 23Elevance Health Offers Great Value
Jan 17At US$483, Is Elevance Health Inc. (NYSE:ELV) Worth Looking At Closely?
Jan 17Elevance Health: Strong And Steady EPS Growth Ahead, High Relative Strength Name
Jan 02Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Nov 28Does Elevance Health (NYSE:ELV) Deserve A Spot On Your Watchlist?
Nov 16Elevance Health to acquire speciality pharmacy from CarepathRx
Nov 09Elevance Health (NYSE:ELV) Is Doing The Right Things To Multiply Its Share Price
Nov 02Elevance Health declares $1.28 dividend
Oct 19Are Investors Undervaluing Elevance Health Inc. (NYSE:ELV) By 37%?
Oct 12Elevance affiliates to offer affordable Medicare Advantage plans
Oct 10Molina, Elevance, Centene win Medicare contracts in California
Aug 26Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Aug 25Elevance Health: Continues To Grow, A Strong Buy
Aug 18What Does Elevance Health Inc.'s (NYSE:ELV) Share Price Indicate?
Aug 13Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$22m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$17m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$5b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$15m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$4b |
| Dec 31 2018 | US$14m | US$1m | US$4b |
| Sep 30 2018 | n/a | n/a | US$5b |
| Jun 30 2018 | n/a | n/a | US$4b |
| Mar 31 2018 | n/a | n/a | US$4b |
| Dec 31 2017 | US$3m | US$162k | US$4b |
Compensación vs. Mercado: La compensación total de Gail($USD21.89M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD13.51M).
Compensación vs. Ingresos: La compensación de Gail ha sido consistente con los resultados de la empresa en el último año.
CEO
Gail Boudreaux (62 yo)
6.5yrs
Permanencia
US$21,889,039
Compensación
Ms. Gail Koziara Boudreaux has been an Independent Director at Target Corporation since September 23, 2021. She has been President, Chief Executive Officer and Director of Elevance Health Inc. (formerly kn...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.5yrs | US$21.89m | 0.062% $ 78.3m | |
| Executive VP & CFO | less than a year | US$12.36m | sin datos | |
| EVP, Chief Legal & Administrative Officer | 3.5yrs | US$8.11m | 0.0044% $ 5.6m | |
| Executive VP and President of Carelon & CarelonRx | 9.9yrs | US$6.98m | 0.0063% $ 7.9m | |
| Executive VP & President of Government Health Benefits | 5.9yrs | US$6.48m | 0.0097% $ 12.3m | |
| SVP, Treasurer & Chief Investment Officer | 6.1yrs | sin datos | sin datos | |
| Senior VP | 8.5yrs | sin datos | 0.00057% $ 720.6k | |
| Chief Information Officer | no data | sin datos | sin datos | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| Senior Vice President of Public Affairs | 10.5yrs | sin datos | sin datos | |
| Chief Strategy Officer & Interim Chief Marketing Officer | less than a year | sin datos | sin datos | |
| Executive VP and President of Commercial & Specialty Health Benefits | no data | sin datos | 0.0050% $ 6.3m |
6.1yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ELV es experimentado (6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.5yrs | US$21.89m | 0.062% $ 78.3m | |
| Independent Director | 19.5yrs | US$386.76k | 0.0027% $ 3.4m | |
| Independent Chair of the Board | 10.6yrs | US$597.83k | 0% $ 0 | |
| Independent Director | 10.8yrs | US$362.53k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$371.42k | 0% $ 0 | |
| Independent Director | 10yrs | US$371.42k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$347.28k | 0.0013% $ 1.6m | |
| Independent Director | 12.8yrs | US$360.34k | 0.0029% $ 3.7m | |
| Member of Advisory Board | 10.8yrs | sin datos | sin datos | |
| Member of Advisory Board | 10.8yrs | sin datos | sin datos | |
| Member of Advisory Board | 10.8yrs | sin datos | sin datos | |
| Member of Advisory Board | 10.8yrs | sin datos | sin datos |
10.8yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de ELV son experimentados ( 10.7 años antigüedad media).